Navigation Links
Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
Date:1/7/2008

g interval, and absorption of oxybutynin is similar when applied to the abdomen, thigh, or upper arm/shoulder.

OTG is protected by two patents, which cover methods of treatment and certain articles of manufacture for treating overactive bladder, with the latest patent expiring in 2020. An additional patent application is pending with the U.S. Patent and Trademark Office and various foreign jurisdictions.

About Overactive Bladder (OAB)

OAB is more common than both diabetes and asthma, affecting more than 33 million Americans. The OAB prescription market in the United States is valued at approximately $1.7 billion. OAB is defined as urgency, with or without urge incontinence and usually includes frequency and nocturia (waking up one or more times during the night to urinate). OAB can force patients to limit their participation in a myriad of physical and social activities, leaving sufferers feeling frustrated, anxious, embarrassed and sleep deprived.

Oxybutynin Topical Gel (OTG)

OTG is a clear, odorless, ethanolic gel that provides for delivery of oxybutynin hydrocholoride in a non-patch transdermal form. OTG is under development for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.

Watson is a Leader in Urology

Making lives more livable, Watson offers patients and healthcare providers investigational and marketed products that address a number of the conditions urologists treat. The Watson portfolio in the U.S. includes Oxytrol(R); Trelstar(R) LA; Trelstar(R) Depot; Androderm(R); ProQuin(R) XR, under a co-promotion agreement with Depomed, Inc.; and AndroGel(R), under a co-promotion agreement with Solvay Pharmaceuticals, Inc. The Watson portfolio also includes a number of products under development including silodosin, a product under development for the treatment of benign prostatic hyperplasia; a six-month formulation of Trelstar(R) (triptorelin pamoate for injectab
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Baxter Announces Recombinant Factor IX Development Program For Hemophilia B
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
5. Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF
6. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
7. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
8. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
9. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
10. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
11. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008).... 1 Vical Incorporated (...$1.0 million milestone payment from Merck & Co...hase I clinical trial of an investigational plasmi... is based on Vical,s DNA gene delivery technology ... (hTERT). hTERT is the subject of separate license...
(Date:11/28/2008)...Nov. 28 Eli Lilly and Co...al New Drug Application (sNDA) from,the U.S. Food...loxetine HCl),for the management of chronic pain....irst half of 2009, adding data from a recently com...ain of the knee. , The decision does not af...
(Date:11/26/2008)... to 406 Subjects , , FRANKLIN, Mass., Nov. ... Bulletin Board: PLCSF) announced today that it ha...ug Administration (FDA) for its U.S. pivotal trial...Guard System(TM) and associated therapy in the pr... , The FDA also approved PLC,s request to ex...
(Date:11/25/2008)...CISCO, Calif., Nov. 25 Proteolix, ...f novel therapeutics that target,protein degradat...day,announced that data from two ongoing Phase 2 ...a will be presented at the upcoming 50th Annual Me.... Carfilzomib is the first in a new class,of spe...
Breaking Medicine Technology:Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Longs Drugs Partners With Google on the Launch of Google Health 19817 1Longs Drugs Partners With Google on the Launch of Google Health 19817 2bioMETRX Expands Engineering and Manufacturing Capabilities 3366 1bioMETRX Expands Engineering and Manufacturing Capabilities 3366 2bioMETRX Expands Engineering and Manufacturing Capabilities 3366 3TAK 390MR Phase 3 data presented at Digestive Disease Week 19814 1TAK 390MR Phase 3 data presented at Digestive Disease Week 19814 2TAK 390MR Phase 3 data presented at Digestive Disease Week 19814 3TAK 390MR Phase 3 data presented at Digestive Disease Week 19814 4Greener offices make happier employees 19812 1Greener offices make happier employees 19812 2
...itional Findings Reported on Glucose Homeostasis E...ne 25, 2007 /PRNewswire-FirstCall/ -- In a 14-day,... doses of the,investigational compound dapaglifloz...ansporter 2 (SGLT2) administered alone or,concomit...tes, no,discontinuations due to adverse events and...
...VILLE, Colo., June 26, 2007 /PRNewswire-FirstCall/...hree Phase I trials,studying REP8839, a novel topi...vity against major skin pathogens including,methic...he Phase I,trials show that topically applied REP8...th low systemic exposure, or drug,absorption into ...
Other Medicine Technology:First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 2First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 3First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 4First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 5First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 6Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 2Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 3Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 4
(Date:12/1/2008)...S, Dec. 2 While many Ame...ic challenges including rising costs of,basic nec...ess Scripts,(Nasdaq: ESRX ) has expanded Rx Out...escription medicines. , (Logo: http://www...OGO ) , Lower-income consumers can now rece...
(Date:12/1/2008)...O New research reveals that computed tomography (...y, has the potential to screen for two diseases at...hich commonly affect adults over age 50. Results o...meeting of the Radiological Society of North Ameri...to screening for colorectal cancer, we were able t...
(Date:12/1/2008)... Warren Presents Award, Engages with President on ...ome and Abroad During Saddleback Civil Forum on Gl...ire/ -- President George W. Bush was honored on th...he "International Medal of PEACE" given by Dr. Ric...uring the Saddleback Civil Forum on Global Health....
(Date:12/1/2008)...ls shut down and stop dividing when their DNA is d... so as to prevent damaged DNA from leading to unre...r, a new study, published in this week,s issue of ...ut down they also spew proteins into their surroun...s up conditions that support the development of ag...
Breaking Medicine News(10 mins):Health News:Amid Economic Crisis, Express Scripts Offers Easy and Affordable Way for Lower-Income Consumers to Get Six-Month Supply of Prescription Medicines 2Health News:Amid Economic Crisis, Express Scripts Offers Easy and Affordable Way for Lower-Income Consumers to Get Six-Month Supply of Prescription Medicines 3Health News:Amid Economic Crisis, Express Scripts Offers Easy and Affordable Way for Lower-Income Consumers to Get Six-Month Supply of Prescription Medicines 4Health News:CT colonography offers 1-stop screening for cancer and osteoporosis 2Health News:President George W. Bush Receives 'International Medal of PEACE' That Coincides With PEPFAR Milestone on World Aids Day: 2Health News:President George W. Bush Receives 'International Medal of PEACE' That Coincides With PEPFAR Milestone on World Aids Day: 3Health News:President George W. Bush Receives 'International Medal of PEACE' That Coincides With PEPFAR Milestone on World Aids Day: 4Health News:President George W. Bush Receives 'International Medal of PEACE' That Coincides With PEPFAR Milestone on World Aids Day: 5Health News:Escape cancer, but age sooner? The dark side of the tumor suppressing process 2
...d the glass jars over the slight incisions on his ... In the ensuing vacuum , the thick dark blood slow...ners. "The Assyrians, the Chinese and the ancient...ing to draw out the corrupt blood," said Hajam as ...
...arch groups described how they had quickly fallen ...ng pregnant making them feel stressed which they ...iving. They also reported becoming anxious that se...e. As the months passed and the couples did not f...
...sing weight to get into shape for her new movie 'K...a 'super-in-shape reporter' in her new movie , had...mits that she didn't like it one bit, and insists ... hardest things she's ever had to do, especially a...
... team of researchers has found evidence that peopl...mon sleep disorder called restless legs syndrome ...loping hypertension. RLS is a common and debilita...ffects the lives of tens of millions of people wor...
Other Medicine News:Health News:Ancient Healing Technique Gains New Popularity in Iraq 2Health News:Research Shows How Women Deal With the Stress When Trying for a Baby! 2Health News:Research Shows How Women Deal With the Stress When Trying for a Baby! 3Health News:Boffins Find Link Between Common Sleep Disorder and Hypertension 2
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
Medicine Products: